English
This article is from Industrial Psychiatry Journal , volume 22 . Abstract Background:: Obsessive-compulsive disorder (OCD) is often refractory to treatment. Glutamatergic neurotransmission modulating agents like memantine, an N-methyl-D-aspartate receptor open channel blocker (antagonist), has been reported to be beneficial in OCD. Materials and Methods:: Twelve subjects of OCD who had been on various medications for over 5 years, but were poor responders, were enrolled for a 12-week open-label trial with fixed dose trial of memantine as an augmenting agent. The OCD symptoms and adverse effects of the drug were monitored. Results:: Out of 12 subjects, eight had clear benefit, with reduction of 25% or more on Yale-Brown Obsessive-Compulsive Scale, and there were no side-effects with the medication, Conclusion:: Memantine may be beneficial for treatment-resistant OCD as an augmenting agent.
Sign in with your free account to read, download EPUBs or listen.
Ebook · An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. · Bakhla, Ajay Kumar, Verma, Vijay, Soren, Subhas, Sarkhel, Sujit, Chaudhury, Suprakash · Internet Archive